Geographic Atrophy GA Market

Geographic atrophy is one of the most common eye disorders in people over 60. It is the final stage of dry age-related macular degeneration (AMD), and it might lead to irreparable retinal loss. In geographic atrophy, a sharply delineated oval or round area of hypopigmentation occurred, and it has a diameter of at least 175 µm. According to a United Nations (UN) report released in December 2020, there were 727 million individuals aged 65 or over in 2020, and it is predicted that this number would increase to 1.5 billion by the year 2050.

The rising life expectancy and falling fertility rates are both contributing to the world's rapidly expanding senior population. Additionally, according to the World Bank, the geriatric population (those over 65) made up 9.3% of the population in 2020, up from 5.9% in 1985.

Furthermore, in developed nations such as the US, the UK, France, Germany, and others have, approximately 1 in 29 people over the age of 75 suffering from geographic atrophy. Thus, older people are at a higher risk of having geographic atrophy. Hence, the increasing geriatric population across the globe is positively impacting the geographic atrophy (GA) market.

The graph that follows illustrates the treatment variations between the pegcetacoplan monthly, every other month, and sham treatment arms overall, as well as according to the tertiles of gender and age. Greater progression (i.e., greater mean change from baseline) is represented by data points on the right-hand side. Moreover, the primary analysis (mixed-effect model) of the sham group in the Phase 2 study shows the geographic atrophy progression as a vertical line. The upper and lower confidence limits of the mean are represented by colored bars.

Geographic Atrophy (GA) Market Segment Insights

Geographic Atrophy (GA) Age Group Insights

The geographic atrophy (GA) market segmentation, based on age group, includes those above 60 years and above 75 years. The above 75 years segment held the majority share in 2021 in the geographic atrophy (GA) market revenue. This is primarily owing to the rising prevalence of geographic atrophy in the above 75 years age group is due to age-related. For instance, according to the Retina Study Group of Portugal, geographic atrophy affects 1.3% of adults between the ages of 75 and 84, rising to approximately 22% by the age of 90.

November 2021 Iveric Bio's(US) avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Geographic Atrophy (GA) Diagnosis Insights

The geographic atrophy (GA) market segmentation is based on diagnosis includes fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), and multifocal electroretinography (MfERG). The optical coherence tomography angiography (OCT-A) segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to optical coherence tomography angiography (OCT-A) has evolved as a non-invasive technology for visualizing the retina's and choroid's microvasculature. It is useful for the diagnosis and understanding of many retinal conditions such as geographic atrophy, diabetic retinopathy, dry age-related macular degeneration, wet age-related macular degeneration, vascular occlusions, and others.

For instance, the AngioVue OCTA system is based on optical coherence tomography angiography offered by Optovue, Inc. (US).

Geographic Atrophy (GA) Therapeutic Agents Clinical Phase Insights

The geographic atrophy (GA) market data has been bifurcated into late-stage (Phase III), Phase II, Phase I, and pre-clinical stage & discovery candidates. The late-stage (Phase III) segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The growth of the biopharmaceutical companies’ segment in the market is mainly due to the Phase III clinical trials used to see if a new medicine or drug combination is better or equal to the current standard of care.

For instance, Galderma Laboratories LP (US), an anti-inflammatory Doxycycline, is being studied in phase III clinical trials for the treatment of geographic atrophy. Hence, rising late-stage (Phase III) clinical trials in the geographic atrophy industry are likely to be the key factor driving the growth of this segment in the market.

September 2021 Apellis Pharmaceuticals, Inc. (US) highlighted the best results from the phase III clinical trial for APL-2 Therapy in geographic atrophy and planned to file a new drug application with the FDA in the first half of 2022.

Geographic Atrophy (GA) Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America geographic atrophy (GA) market is expected to account for USD XX billion in 2021 and is expected to exhibit an XX% CAGR during the study period. This is attributed to the rising investment in the healthcare industry and the presence of major key players in the region such as Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals Inc. (US), and others.

Moreover, the rising number of patients suffering from geographic atrophy and growing government initiatives related to geographic atrophy in the region further fuel the growth of the market.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Europe geographic atrophy (GA) market is expected to account for the second-largest market share due to the rising older population, increasing demand for technologically innovative treatment, and growing R&D investment by the biopharmaceutical industry. Further, the Germany geographic atrophy (GA) market is expected to hold third place for the market share, and the UK geographic atrophy (GA) market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France geographic atrophy (GA) market will hold the 5th place for the market share.

The Asia-Pacific geographic atrophy (GA) market is expected to grow at a CAGR of XX% from 2022 to 2030. This is due to the developing healthcare infrastructure, the establishment of research organizations, and the rising prevalence of AMD disorders among the elderly population. Moreover, China geographic atrophy (GA) market is expected to hold the largest market share, and the India geographic atrophy (GA) market is expected fastest-growing market in the Asia-Pacific region.

For instance, According to World Health Organization (WHO), 90% of the total visually impaired people live in developing countries such as China, India, and others, to become the leader in the geographic atrophy (GA) market.

The Rest of the World includes the Middle East, Africa, and Latin America. Government initiatives to increase medical expenditure and increase healthcare infrastructure in the region contribute to the growth of the geographic atrophy (GA) market.

The Global Geographic Atrophy (GA) Market Industry is projected to experience substantial growth over the next decade. With a market size anticipated to reach 22.7 USD Billion in 2024 and further expand to 44.8 USD Billion by 2035, the industry is on a promising trajectory. The compound annual growth rate (CAGR) of 6.4% from 2025 to 2035 indicates a robust market environment driven by various factors, including advancements in treatment, increased healthcare spending, and demographic shifts. This growth presents opportunities for stakeholders to innovate and enhance patient care in geographic atrophy.

The Global Geographic Atrophy (GA) Market Industry benefits from rising healthcare expenditures across various regions. Governments and private sectors are investing more in ophthalmic care, particularly for chronic conditions like geographic atrophy. This trend is evident in countries with aging populations, where healthcare budgets are allocated to improve access to diagnostics and treatments. As a result, the market is expected to grow at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2035. This increase in funding not only enhances patient care but also stimulates research and development in the field of GA.

Innovations in treatment options for geographic atrophy are significantly influencing the Global Geographic Atrophy (GA) Market Industry. Recent developments in pharmacological therapies, including complement inhibitors and gene therapies, show promise in slowing disease progression. Clinical trials are underway, with several candidates demonstrating potential efficacy. As these treatments become available, they are likely to enhance patient outcomes and increase market size. The anticipated growth trajectory suggests that by 2035, the market may expand to 44.8 USD Billion, reflecting the impact of these advancements on patient management and healthcare strategies.

Emerging markets are becoming increasingly relevant to the Global Geographic Atrophy (GA) Market Industry as demographic shifts occur. Countries in Asia and Latin America are experiencing rapid urbanization and aging populations, which may lead to a rise in GA cases. These regions are beginning to invest in healthcare infrastructure and ophthalmic services, creating opportunities for market growth. The combination of demographic changes and economic development suggests that the GA market will see increased activity in these areas, potentially altering the global landscape of geographic atrophy management.

The Global Geographic Atrophy (GA) Market Industry is positively impacted by heightened awareness and the implementation of screening programs for eye diseases. Public health initiatives aimed at educating populations about the risks and symptoms of geographic atrophy are crucial. Increased screening leads to earlier diagnosis and intervention, which can significantly alter disease progression. As awareness grows, more individuals seek medical advice, thereby driving demand for treatments. This proactive approach is likely to contribute to the market's expansion, as healthcare providers prioritize early detection and management of GA.

The Global Geographic Atrophy (GA) Market Industry is witnessing a surge in demand due to the increasing prevalence of age-related macular degeneration (AMD). As populations age, particularly in developed nations, the incidence of AMD rises, leading to a higher number of patients experiencing geographic atrophy. This condition is projected to affect millions globally, with estimates suggesting that by 2024, the market could reach 22.7 USD Billion. The growing awareness and diagnosis of AMD further contribute to the expansion of the GA market, as healthcare systems adapt to manage this chronic condition more effectively.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America geographic atrophy (GA) market is expected to account for USD XX billion in 2021 and is expected to exhibit an XX% CAGR during the study period. This is attributed to the rising investment in the healthcare industry and the presence of major key players in the region such as Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals Inc. (US), and others.

Moreover, the rising number of patients suffering from geographic atrophy and growing government initiatives related to geographic atrophy in the region further fuel the growth of the market.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 GEOGRAPHIC ATROPHY (GA) MARKET SHARE BY REGION 2021 (%)

Source Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe geographic atrophy (GA) market is expected to account for the second-largest market share due to the rising older population, increasing demand for technologically innovative treatment, and growing R&D investment by the biopharmaceutical industry. Further, the Germany geographic atrophy (GA) market is expected to hold third place for the market share, and the UK geographic atrophy (GA) market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France geographic atrophy (GA) market will hold the 5th place for the market share.

The Asia-Pacific geographic atrophy (GA) market is expected to grow at a CAGR of XX% from 2022 to 2030. This is due to the developing healthcare infrastructure, the establishment of research organizations, and the rising prevalence of AMD disorders among the elderly population. Moreover, China geographic atrophy (GA) market is expected to hold the largest market share, and the India geographic atrophy (GA) market is expected fastest-growing market in the Asia-Pacific region.

For instance, According to World Health Organization (WHO), 90% of the total visually impaired people live in developing countries such as China, India, and others, to become the leader in the geographic atrophy (GA) market.

The Rest of the World includes the Middle East, Africa, and Latin America. Government initiatives to increase medical expenditure and increase healthcare infrastructure in the region contribute to the growth of the geographic atrophy (GA) market.

The presence of major market players in the Geographic Atrophy (GA) market is characterized by the presence of many international, regional, and local players. growing geriatric population and increasing prevalence of geographic atrophy, and increased healthcare expenditure globally. In addition, the companies are investing in R&D activities to expand their product portfolio for GA, which further drives the growth of the geographic atrophy market. Moreover, the vendors compete based on cost, product quality, reliability, and aftermarket services and try to be the first to bring a treatment for the public.

It is crucial for the players to offer cost-efficient and high-quality products for geographic atrophy to succeed in an intensely competitive market environment.

One of the primary business strategies adopted by manufacturers in the geographic atrophy (GA) industry to benefit clients and expand the geographic atrophy (GA) market sector is to manufacture locally to reduce operating costs.

Genentech, Inc. is a biotechnology company dedicated to discovering and developing medicines for patients suffering from serious and potentially fatal illnesses. Genentech is a wholly owned subsidiary of Roche Holding Ltd. Genentech conducts research, develops, manufactures, and distributes human pharmaceuticals to address important medical needs. The company produces animals from gene cells that would not typically be produced by the cell, and it has six offices across the U. S.

For instance, in December 2022, Genentech (US) Launches Phase 2a Study of RG6501 (OpRegen) in Patients with Geographic Atrophy. a phase 2a, multicenter, open-label, single-arm clinical study of RG6501 (OpRegen), a retinal pigment epithelial cell therapy. The goal of the trial is to assess the safety and efficacy of OpRegen in up to 60 patients with geographic atrophy (GA) brought on by age-related macular degeneration. The study will examine the best subretinal surgical delivery method.

Also, Iveric Bio (US) is a biopharmaceutical company dedicated to the research and creation of innovative therapies for retinal conditions with unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases or IRDs. In June 2022, Iveric Bio's(US) positive topline data from Zimura GATHER2 Phase 3 clinical trial in geographic atrophy.